Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol (Strasbourg University Hospital)
- Development stage
- Unknown
- Lead developer
- Strasbourg University Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
This entry refers to a group of antipsychotic medications—olanzapine, zuclopenthixol, risperidone, pipotiazine, quetiapine, and flupentixol—that are being evaluated in the **DREAMS-Phen** (Antipsychotic Dose Reduction vs Maintenance in Schizophrenia) clinical trial. Led by the **Strasbourg University Hospital**, this prospective, randomized, and controlled study compares two treatment strategies: gradual dose reduction versus maintenance treatment in patients with schizophrenia spectrum disorders who have achieved clinical stability. The study stratifies patients based on their psychotic phenotype (cycloid psychosis vs. non-cycloid psychosis) to determine if a personalized medicine approach can improve functional remission. The medications listed include both first-generation (typical) and second-generation (atypical) antipsychotics, which primarily act by modulating dopaminergic and serotonergic neurotransmission.
- Other names
- olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flup
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol (Strasbourg University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol (Strasbourg University Hospital).